FRAXA invites investigator-initiated research applications for innovative pilot studies aimed at developing and characterising new therapeutic approaches for the treatment and ultimate cure of fragile X syndrome.
The highest priority is given to clinical trials of potentially disease-modifying therapeutics which have previously been validated in fragile X animal models.
Funding & Duration
Grants are flexible in amount and duration. Applications are ranked based on relative value, so smaller requests have an advantage.
Must involve human subjects with fragile X.
Available to researchers internationally.
- Letter of Intent (LOI) is essential, and may be submitted directly to the Sponsor at anytime.
- Full applications may be submitted at any time, subject to an internal review.
- Submit an Application to the Research Branch for Review